Geron Inc. (NASDAQ: GERN) stock gained by 5.97% at last close while THE GERN stock price further rises during pre-market by 0.70%. Geron is a clinical-stage biopharmaceutical business aimed at the development and marketing of imetelstat, a first-in-class telomerase inhibitor, in hematologic myeloid malignancies. IMerge in lower-risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis are two Phase 3 clinical studies now underway at GERN.
What is happening?
GERN announced today that two posters presenting novel clinical data and analysis linked to imetelstat which is GERN’s first-in-class telomerase inhibitor will be presented at the European Hematology Association Annual Congress, which will be conducted electronically from June 9 to 17. On the EHA website, you can get the abstracts for the posters. On June 11, 2021, both posters will be uploaded on the EHA Virtual Congress website.
Aleksandra Rizo, Geron’s Chief Medical Officer commented:
GERN is thrilled that the EHA approved both of their papers, allowing them to highlight imetelstat’s compelling potential to become a leading therapy for MDS and MF patients with lower risk. The latest results and analysis from their Phase 2 IMbark and IMerge studies indicate imetelstat’s disease-modifying efficacy and ability to deliver extraordinary therapeutic benefits, such as long-term transfusion independence in lower-risk MDS patients and improved overall lifespan in MF patients. GERN is looking forward to the presentations and remain certain that imetelstat, with its unique telomerase inhibition mode of action, is a highly distinct medication that can significantly improve patient outcomes.
Imetelstat is a new, first-in-class telomerase inhibitor being produced for hematologic myeloid malignancies by Geron. Imetelstat attacks telomerase to prevent the unregulated multiplication of malignant stem and progenitor cells in hematologic myeloid malignancies, leading in malignant cell death and possible disease-modifying effect, according to data from Phase 2 clinical studies.